The new 10-year contract will focus on strengthening the partnership for continued transformative innovation for patients
Phase I data for tuvusertib, lead asset from the company’s unique portfolio of DDR inhibitors
Acquisition will advance Merck’s integrated offering for viral vector manufacturing
Sanofi will leverage this partnership to provide access to proprietary data to develop AI models
The collaboration aims to bolster healthcare entrepreneurship
Annapurna will lead the company in India ensuring patient access to its highly innovative medicines and vaccines
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Achira is engaged in development and commercialization of PoC medical test kits in India
Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s
These devices instantly detect various arrhythmias, including atrial fibrillation (Afib), bradycardia, tachycardia, and more
Subscribe To Our Newsletter & Stay Updated
